KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLong-Term Debt IssuancesR&D In ProcessReceivables - NetReceivables - Other
Ratios

Eli Lilly (LLY) EBIAT (2016 - 2025)

Eli Lilly's EBIAT history spans 17 years, with the latest figure at $6.6 billion for Q4 2025.

  • For Q4 2025, EBIAT rose 50.52% year-over-year to $6.6 billion; the TTM value through Dec 2025 reached $20.6 billion, up 94.9%, while the annual FY2025 figure was $20.6 billion, 94.9% up from the prior year.
  • EBIAT reached $6.6 billion in Q4 2025 per LLY's latest filing, up from $5.6 billion in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $6.6 billion in Q4 2025 to a low of -$57.4 million in Q3 2023.
  • Average EBIAT over 5 years is $2.4 billion, with a median of $1.8 billion recorded in 2022.
  • Peak YoY movement for EBIAT: tumbled 103.95% in 2023, then soared 1790.42% in 2024.
  • A 5-year view of EBIAT shows it stood at $1.7 billion in 2021, then rose by 12.26% to $1.9 billion in 2022, then increased by 12.98% to $2.2 billion in 2023, then skyrocketed by 101.43% to $4.4 billion in 2024, then soared by 50.52% to $6.6 billion in 2025.
  • Per Business Quant, the three most recent readings for LLY's EBIAT are $6.6 billion (Q4 2025), $5.6 billion (Q3 2025), and $5.7 billion (Q2 2025).